Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Altered expression of centromere protein-A (CENP-A) is observed in various types of human cancers. However, the clinical significance and pathological role of CENP-A in epithelial ovarian cancer (EOC) remains unclear. The main objective of this investigation was to clarify the relationships between CENP-A expression and the clinicopathological features of patients with EOC. Real-time quantitative PCR and Western blot were performed to examine CENP-A expression in 20 pairs of fresh-frozen EOC tissues and corresponding noncancerous tissues. Using immunohistochemistry, we performed a retrospective study of the CENP-A expression levels on 120 archival EOC paraffin-embedded samples. Prognostic outcomes correlated with CENP-A were examined using Kaplan–Meier analysis and Cox proportional hazards model. Our results showed that the expression levels of CENP-A mRNA and protein in EOC tissues were both significantly higher than those in noncancerous tissues. By immunohistochemistry, the data revealed that high CENP-A expression was significantly correlated with pathological grade (P = 0.02) and International Federation of Gynecology and Obstetrics stage (P = 0.006). Consistent with these results, we found that high expression of CENP-A was significantly correlated with poor survival in EOC patients (P < 0.001). Furthermore, Cox regression analyses showed that CENP-A expression was an independent predictor of overall survival. Our data suggest that CENP-A could play an important role in EOC and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010;46:170–9. doi:10.1016/j.ejca.2009.10.003.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 2011;71:349–59. doi:10.1158/0008-5472.CAN-10-2550.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010;16:5320–8. doi:10.1158/1078-0432.CCR-10-0974.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol. 2011;122:366–71. doi:10.1016/j.ygyno.2011.04.033.

    Article  CAS  PubMed  Google Scholar 

  5. Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, et al. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett. 2007;246:190–200. doi:10.1016/j.canlet.2006.02.018.

    Article  CAS  PubMed  Google Scholar 

  6. Black BE, Jansen LE, Maddox PS, Foltz DR, Desai AB, Shah JV, et al. Centromere identity maintained by nucleosomes assembled with histone H3 containing the CENP-A targeting domain. Mol Cell. 2007;25:309–22. doi:10.1016/j.molcel.2006.12.018.

    Article  CAS  PubMed  Google Scholar 

  7. Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One. 2011;6:e17794. doi:10.1371/journal.pone.0017794.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Tomonaga T, Matsushita K, Yamaguchi S, Oohashi T, Shimada H, Ochiai T, et al. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003;63:3511–6.

    CAS  PubMed  Google Scholar 

  9. Wu Q, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of centromere protein A in human lung adenocarcinoma. Lung Cancer. 2012;77:407–14. doi:10.1016/j.lungcan.2012.04.007.

    Article  PubMed  Google Scholar 

  10. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012;14:R72. doi:10.1186/bcr3181.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:919–27. doi:10.1007/s10552-012-9963-4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, et al. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecol Oncol. 2012;125:758–63. doi:10.1016/j.ygyno.2012.03.031.

    Article  CAS  PubMed  Google Scholar 

  13. Wang M, He Y, Shi L, Shi C. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32:171–7.

    PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gynecology and Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Obstetrics and Gynecology Hospital of Fudan University, No. 419, Fangxie Rd, Shanghai, 200011, China

    Jun-Jun Qiu, Tian-Jiao Lv, Hong-Yan Jin, Jing-Xin Ding, Wei-Wei Feng, Ying Zhang & Ke-Qin Hua

  2. School of Life Sciences and Technology of Tongji University, Shanghai, 200092, China

    Jun-Jie Guo

Authors
  1. Jun-Jun Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-Jie Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tian-Jiao Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong-Yan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing-Xin Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-Wei Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ke-Qin Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ke-Qin Hua.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qiu, JJ., Guo, JJ., Lv, TJ. et al. Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer. Tumor Biol. 34, 2971–2975 (2013). https://doi.org/10.1007/s13277-013-0860-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0860-6

Keywords

Search

Navigation